Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody_Chinese Journal of Ocular Fundus Diseases

Authors：

 Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association

Corresponding author：

Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association, Email: xzhang08@tmu.edu.cn

Keywords：

Non-infectious uveitis; Anti-tumor necrosis factor-α monoclonal antibody; Adalimumab; Inflixmab; Biologicals; Expert consensus

DOI：

10.3760/cma.j.cn511434-20231201-00473

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Anti-tumor necrosis factor-α monoclonal antibody agents have been widely applied in the management of autoimmune diseases. Among them, Adalimumab and Infliximab have been used for years in clinical practice in treating non-infectious uveitis and achieved satisfactory effects and safety. However, no guideline or expert consensus for their usage is available in China currently. It hopefully promotes standardized clinical application of anti-tumor necrosis factor -α monoclonal antibody in treating non-infectious uveitis, together with other senior experts in uveitis, the Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association form this evidence-based recommendations for clinicians’ reference.

Citation： Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association. Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody. Chinese Journal of Ocular Fundus Diseases, 2024, 40(1): 8-19. doi: 10.3760/cma.j.cn511434-20231201-00473 Copy

1.	Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244-279. DOI: 10.1016/j.pharmthera.2007.10.001.
2.	Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents-comparison among therapeutic TNF-α antagonists[J]. Cytokine, 2018, 101: 56-63. DOI: 10.1016/j.cyto.2016.08.014.
3.	Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932-943. DOI: 10.1056/NEJMoa1509852.
4.	Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10050): 1183-1192. DOI: 10.1016/S0140-6736(16)31339-3.
5.	Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of Adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL Ⅲ[J]. Ophthalmology, 2018, 125(7): 1075-1087. DOI: 10.1016/j.ophtha.2017.12.039.
6.	Li B, Li H, Zhang L, et al. Efficacy and safety of Adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials[J/OL]. Front Pharmacol, 2021, 12: 673984[2021-04-26]. https://pubmed.ncbi.nlm.nih.gov/33981245/. DOI: 10.3389/fphar.2021.673984.
7.	Xiong A, Liu D, Chen H, et al. The efficacy and safety of Infliximab in refractory noninfectious uveitis: a meta-analysis of observational studies[J/OL]. Front Pharmacol, 2021, 12: 620340[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34603013/. DOI: 10.3389/fphar.2021.620340.
8.	Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up[J]. Ophthalmology, 2014, 121(1): 358-364. DOI: 10.1016/j.ophtha.2013.07.019.
9.	Maleki A, Sahawneh HF, Ma L, et al. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy[J]. Retina, 2017, 37(5): 836-843. DOI: 10.1097/IAE.0000000000001269.
10.	Corredores Dieb J, Vofo B, Amer R. Long-term experience with anti-tumor necrosis factor-α therapy in the treatment of refractory, non-infectious intermediate, posterior, and panuveitis[J]. Ocul Immunol Inflamm, 2022, 20: 1-8. DOI: 10.1080/09273948.2022.2152983.
11.	Al-Janabi A, El Nokrashy A, Sharief L, et al. Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis[J]. Ophthalmology, 2020, 127(3): 410-416. DOI: 10.1016/j.ophtha.2019.08.031.
12.	Maalouf G, Andrillon A, Leclercq M, et al. Lower relapses rate with Infliximab versus Adalimumab in sight-threatening uveitis: a multicenter study of 330 patients[J]. Am J Ophthalmol, 2022, 238: 173-180. DOI: 10.1016/j.ajo.2022.02.002.
13.	Vallet H, Seve P, Biard L, et al. Infliximab versus Adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network[J]. Arthritis Rheumatol, 2016, 68(6): 1522-1530. DOI: 10.1002/art.39667.
14.	Fabiani C, Sota J, Rigante D, et al. Efficacy of Adalimumab and Infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies[J]. Clin Rheumatol, 2018, 37(10): 2805-2809. DOI: 10.1007/s10067-018-4133-z.
15.	Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients[J]. Clin Rheumatol, 2019, 38(2): 407-415. DOI: 10.1007/s10067-018-4228-6.
16.	Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders[J]. Ophthalmology, 2014, 121(3): 785-796. DOI: 10.1016/j.ophtha.2013.09.048.
17.	Osswald D, Rameau AC, Terzic J, et al. Risk factors leading to anti-TNF Alpha therapies in pediatric severe uveitis[J/OL]. Front Pediatr, 2022, 10: 802977[2022-03-04]. https://pubmed.ncbi.nlm.nih.gov/35311049/. DOI: 10.3389/fped.2022.802977.
18.	Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative[J]. Ophthalmology, 2018, 125(5): 757-773. DOI: 10.1016/j.ophtha.2017.11.017.
19.	Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490. DOI: 10.1080/14712598.2019.1595578.
20.	Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease[J/OL]. Nat Commun, 2023, 14(1): 3768[2023-06-24]. https://pubmed.ncbi.nlm.nih.gov/37355662/. DOI: 10.1038/s41467-023-39483-5.
21.	Sener H, Evereklioglu C, Horozoglu F, et al. Efficacy and safety of Adalimumab in patients with Behçet uveitis: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2023, 10: 1-9. DOI: 10.1080/09273948.2022.2157288.
22.	Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations[J]. Rheumatology, 2007, 46(5): 736-741. DOI: 10.1093/rheumatology/kem034.
23.	Hu Y, Huang Z, Yang S, et al. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets' disease-associated uveitis: a systematic review and meta-analysis[J/OL]. Front Pharmacol, 2020, 11, 941[2020-06-24]. https://pubmed.ncbi.nlm.nih.gov/32670062/. DOI: 10.3389/fphar.2020.00941.
24.	Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet's disease following withdrawal of successful anti-tumor necrosis factor treatment[J]. Arthritis Rheumatol, 2017, 69(12): 2380-2385. DOI: 10.1002/art.40235.
25.	Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Behçet's disease[J]. Orphanet J Rare Dis, 2021, 16(Suppl 1): S352. DOI: 10.1186/s13023-020-01620-4.
26.	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. DOI: 10.1136/annrheumdis-2018-213225.
27.	Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis[J]. N Engl J Med, 2017, 376(17); 1637-1646. DOI: 10.1056/NEJMoa1614160.
28.	AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use: US prescribing information[EB/OL]. (2014-09-22)[2023-12-01]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s356lbl.pdf.
29.	AbbVie Ltd. HUMIRA [Summary of Product Characteristics][EB/OL]. (2022-10-11) [2023-12-01]. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product- information_en.pdf.
30.	Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of Adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003-1011. DOI: 10.1136/annrheumdis-2017-212089.
31.	Heiligenhaus A, Klotsche J, Tappeiner C, et al. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis (ICON-JIA) study[J]. Rheumatology, 2019, 58(6): 975-986. DOI: 10.1093/rheumatology/key406.
32.	Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
33.	Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2007, 66(4): 548-550. DOI: 10.1136/ard.2006.058248.
34.	Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab for juvenile idiopathic arthritis-associated uveitis[J]. Clin Exp Ophthalmol, 2005, 33(5): 461-468. DOI: 10.1111/j.1442-9071.2005.01062.x.
35.	Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey[J]. J Rheumatol, 2007, 34(5): 1146-1150.
36.	Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis[J]. Pediatr Rheumatol Online J, 2019, 17(1): 79. DOI: 10.1186/s12969-019-0383-9.
37.	Li Y, Mao X, Tang X, et al. Efficacy and safety of anti-TNFα therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis[J]. Rheumatol Ther, 2021, 8(2): 711-727. DOI: 10.1007/s40744-021-00296-x.
38.	Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of Adalimumab and Infliximab for uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2018, 45(8): 1167-1172. DOI: 10.3899/jrheum.171006.
39.	Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management[J]. Biomedicines, 2023, 11(2): 629. DOI: 10.3390/biomedicines11020629.
40.	Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131.
41.	Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res, 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
42.	Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis[J]. Arthritis Care Res, 2019, 71(6): 703-716. DOI: 10.1002/acr.23871.
43.	Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus[J]. Rheumatol Int, 2015, 35(5): 777-785. DOI: 10.1007/s00296-015-3231-3.
44.	中华医学会儿科学分会免疫学组, 中国儿童风湿免疫病联盟, 国家儿童健康与疾病临床研究中心风湿免疫联盟. 幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)[J]. 协和医学杂志, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.The Subspecialty Group of Immunology, the Society of Pediatrics, Chinese Medical Association, Chinese Alliance of Pediatric Rheumatic and Immunologic Diseases, Alliance of Rheumatic and Immunologic Diseases, National Clinical Research Center for Child Health and Disorders. Chinese Expert Consensus on Juvenile Idiopathic Arthritis-associated Uveitis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.
45.	Vitale A, Casa FD, Guerriero S, et al. Efficacy and safety of Adalimumab in pediatric non-infectious non-anterior uveitis: real-life experience from the international AIDA network uveitis registry[J]. Ophthalmol Ther, 2023, 12(4): 1957-1971. DOI: 10.1007/s40123-023-00712-1.
46.	Ozer MD, Batur M. Anti-tumor necrosis factor-alpha treatment in pediatric patients with pars planitis: a single-center experience from turkey[J]. Int Ophthalmol, 2023, 43(1): 155-166. DOI: 10.1007/s10792-022-02398-z.
47.	Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis[J]. Ophthalmology, 2006, 113(5): 860-864. DOI: 10.1016/j.ophtha.2006.01.005.
48.	Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up[J]. Am J Ophthalmol, 2007, 144(6): 844-849. DOI: 10.1016/j.ajo.2007.08.018.
49.	Ucan Gunduz G, Yalcinbayir O, Cekic S, et al. Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: Infliximab versus Adalimumab[J]. J Ocul Pharmacol Ther, 2021, 37(4): 236-240. DOI: 10.1089/jop.2020.0081.
50.	Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with Adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
51.	Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-Adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
52.	Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
53.	Al-Julandani DA, Bagri NK, Tsang N, et al. Outcome of adalimumab monotherapy in paediatric non-infectious uveitis[J]. Pediatr Rheumatol Online J, 2023, 21(1): 21. DOI: 10.1186/s12969-023-00794-y.
54.	Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study[J/OL]. Mediators Inflamm, 2019, 10: 1623847[2019-02-10]. https://pubmed.ncbi.nlm.nih.gov/30881221/. DOI: 10.1155/2019/1623847.
55.	Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study[J]. Br J Ophthalmol, 2018, 102(5): 637-641. DOI: 10.1136/bjophthalmol-2017-310733.
56.	Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease[J]. Ocul Immunol Inflamm, 2012, 20(3): 193-197. DOI: 10.3109/09273948.2012.665124.
57.	Horiguchi N, Kamoi K, Horie S, et al. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome[J/OL]. Sci Rep, 2020, 10(1): 22227[2020-12-17]. https://pubmed.ncbi.nlm.nih.gov/33335139/. DOI: 10.1038/s41598-020-78718-z.
58.	Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies[J]. Ophthalmology, 2016, 123(12): 2618-2625. DOI: 10.1016/j.ophtha.2016.08.025.
59.	Marino A, Real-Fernández F, Rovero P, et al. Anti-Adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations[J]. Clin Rheumatol, 2018, 37(5): 1407-1411. DOI: 10.1007/s10067-018-4057-7.
60.	Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of Infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study[J]. Rheumatology, 2007, 46(7): 1161-1164. DOI: 10.1093/rheumatology/kem101.
61.	Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis[J]. Surv Ophthalmol, 2015, 60(6): 575-589. DOI: 10.1016/j.survophthal.2015.06.004.
62.	Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis[J]. Arthritis Care Res, 2023, 75(5): 975-982. DOI: 10.1002/acr.24963.
63.	Kalinina Ayuso V, van de Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis[J]. Am J Ophthalmol, 2011, 151(2): 217-222. DOI: 10.1016/j.ajo.2010.08.021.
64.	Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions[J]. Int Ophthalmol, 2010, 30(5): 577-581. DOI: 10.1007/s10792-010-9372-1.
65.	Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with Infliximab[J]. Ocul Immunol Inflamm, 2013, 21(6): 468-474. DOI: 10.3109/09273948.2013.779727.
66.	Breitbach M, Tappeiner C, Böhm MR, et al. Discontinuation of long-term Adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(1): 171-177. DOI: 10.1007/s00417-016-3497-5.
67.	De Simone L, Invernizzi A, Aldigeri R, et al. Effectiveness of Infliximab and interferon alpha-2a for the treatment of Behçet's uveitis: customizing therapy according to the clinical features[J]. Ocul Immunol Inflamm, 2022, 30(2): 506-514. DOI: 10.1080/09273948.2020.1815797.
68.	Doycheva D, Zierhut M, Blumenstock G, et al. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results[J]. Br J Ophthalmol, 2014, 98(4): 523-528. DOI: 10.1136/bjophthalmol-2013-303935.
69.	Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-term follow-up of patients with uveitis treated with Adalimumab: response rates and reasons for discontinuation of therapy[J]. Am J Ophthalmol, 2022, 240: 194-204. DOI: 10.1016/j.ajo.2022.03.017.
70.	Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of Infliximab[J]. Ocul Immunol Inflamm, 2014, 22(2): 96-101. DOI: 10.3109/09273948.2013.812222.
71.	Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy[J]. Jpn J Ophthalmol, 2014, 58(1): 75-80. DOI: 10.1007/s10384-013-0283-3.
72.	Köse HC, Yalçındağ N. Clinical follow-up of patients with Behçet uveitis after discontinuation of Infliximab therapy[J]. Ocul Immunol Inflamm, 2022, 30(1): 203-207. DOI: 10.1080/09273948.2020.1774907.
73.	Mercier AE, Ribeiro E, Korobelnik JF, et al. Efficacy of anti-TNF-α therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients[J]. Ocul Immunol Inflamm, 2018, 26(3): 477-484. DOI: 10.1080/09273948.2016.1236968.
74.	Lerman MA, Lewen MD, Kempen JH, et al. Uveitis reactivation in children treated with tumor necrosis factor Alpha inhibitors[J]. Am J Ophthalmol, 2015, 160(1): 193-200. DOI: 10.1016/j.ajo.2015.04.016.
75.	Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Behçet's disease[J]. Ophthalmology, 2018, 125(9): 1444-1451. DOI: 10.1016/j.ophtha.2018.02.020.
76.	Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of Infliximab in refractory uveitis due to Behçet disease: national study of 103 white patients[J]. J Rheumatol, 2021, 48(5): 741-750. DOI: 10.3899/jrheum.200300.
77.	Neves LM, Haefeli LM, Hopker LM, et al. Monitoring and treatment of juvenile idiopathic arthritis-associated uveitis: brazilian evidence-based practice guidelines[J]. Ocul Immunol Inflamm, 2022, 30(6): 1384-1398. DOI: 10.1080/09273948.2021.1876886.
78.	Roberts JE, Nigrovic PA, Lo MS, et al. Weekly Adalimumab, an effective alternative for refractory uveitis in children[J/OL]. J Clin Rheumatol, 2022, 28(1): e301-e304[2022-01-01]. https://pubmed.ncbi.nlm.nih.gov/33790207/. DOI: 10.1097/RHU.0000000000001707.
79.	Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis[J]. Clin Rheumatol, 2018, 37(2): 549-553. DOI: 10.1007/s10067-017-3890-4.
80.	Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study[J]. Ophthalmology, 2014, 121(10): 1877-1884. DOI: 10.1016/j.ophtha.2014.04.042.
81.	Tambralli A, Beukelman T, Weiser P, et al. High doses of Infliximab in the management of juvenile idiopathic arthritis[J]. J Rheumatol, 2013, 40(10): 1749-1755. DOI: 10.3899/jrheum.130133.
82.	Cunningham ET, Pavesio CE, Goldstein DA, et al. Multiple sclerosis-associated uveitis[J]. Ocul Immunol Inflamm, 2004, 25(3): 299-301.
83.	Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers[J]. Curr Neurol Neurosci Rep, 2017, 17(4): 36. DOI: 10.1007/s11910-017-0742-1.
84.	Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies[J]. Rheumatology, 2010, 49(11): 2217-2219. DOI: 10.1093/rheumatology/keq249a.
85.	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021)[J]. 中华皮肤科杂志, 2021, 54(12): 1033-1047. DOI: 10.35541/cjd.20210643.Chinese Medical Association Dermatology and venereology Branch, Chinese Medical Doctor Association Dermatology Branch, Chinese Association of Integrated Traditional and Western Medicine Dermatology and venereology Professional Committee. Guidelines for the treatment of psoriasis with biologic agents in China (2021)[J]. Chin J Dermat, 2021, 54(12): 1033-1047. DOI: 10.35541/cjd.20210643.
86.	Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, et al. The role of TNF-α and anti-TNF-α agents during preconception, pregnancy, and breastfeeding[J/OL]. Int J Mol Sci, 2021, 22(6): 2922[2021-03-13]. https://pubmed.ncbi.nlm.nih.gov/33805757/. DOI: 10.3390/ijms22062922.
87.	Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases[J]. Arthritis Rheumatol, 2020, 72(4): 529-556. DOI: 10.1002/art.41191.
88.	Götestam Skorpen C, Hoeltzenbein M, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016, 75(5): 795-810. DOI: 10.1136/annrheumdis-2015-208840.
89.	Tosi GM, Sota J, Vitale A, Rigante D, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis[J]. Clin Exp Rheumatol, 2019, 37(4): 680-683.
90.	Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients[J/OL]. RMD Open, 2022, 8(2): e002693[2022-12-01]. https://pubmed.ncbi.nlm.nih.gov/36597972/. DOI: 10.1136/rmdopen-2022-002693.
91.	Leal I, Steeples LR, Wong SW, et al. Update on the systemic management of non-infectious uveitis in children and adolescents[J]. Surv Ophthalmol, 2023, 69(1): 103-121. DOI: 10.1016/j.survophthal.2023.01.002.
92.	Pocock JM, Vasconcelos JC, Ostör AJ, et al. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?[J]. Rheumatology, 2008, 47(7): 1073-1076. DOI: 10.1093/rheumatology/ken204.
93.	Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary[J]. Rheumatology, 2019, 58(2): 220-226. DOI: 10.1093/rheumatology/key207.
94.	中国炎症性肠病诊疗质控评估中心, 中华医学会消化病学分会炎症性肠病学组. 生物制剂治疗炎症性肠病专家建议意见[J]. 中华炎性肠病杂志, 2021, 5(3): 193-206. DOI: 10.3760/cma.j.cn101480-20210702-00052.Chinese Inflammatory bowel Disease Diagnosis and Treatment Quality Control Evaluation Center, Chinese Medical Association Gastroenterology Branch Inflammatory Bowel Group. Consensus on biological agents in treating patients with inflammatory bowel disease[J]. Chin J Inflammat Bowel Dis, 2021, 5(3): 193-206. DOI: 10.3760/cma.j.cn101480-20210702-00052.

1. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244-279. DOI: 10.1016/j.pharmthera.2007.10.001.
2. Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents-comparison among therapeutic TNF-α antagonists[J]. Cytokine, 2018, 101: 56-63. DOI: 10.1016/j.cyto.2016.08.014.
3. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932-943. DOI: 10.1056/NEJMoa1509852.
4. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL Ⅱ): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2016, 388(10050): 1183-1192. DOI: 10.1016/S0140-6736(16)31339-3.
5. Suhler EB, Adán A, Brézin AP, et al. Safety and efficacy of Adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL Ⅲ[J]. Ophthalmology, 2018, 125(7): 1075-1087. DOI: 10.1016/j.ophtha.2017.12.039.
6. Li B, Li H, Zhang L, et al. Efficacy and safety of Adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials[J/OL]. Front Pharmacol, 2021, 12: 673984[2021-04-26]. https://pubmed.ncbi.nlm.nih.gov/33981245/. DOI: 10.3389/fphar.2021.673984.
7. Xiong A, Liu D, Chen H, et al. The efficacy and safety of Infliximab in refractory noninfectious uveitis: a meta-analysis of observational studies[J/OL]. Front Pharmacol, 2021, 12: 620340[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34603013/. DOI: 10.3389/fphar.2021.620340.
8. Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up[J]. Ophthalmology, 2014, 121(1): 358-364. DOI: 10.1016/j.ophtha.2013.07.019.
9. Maleki A, Sahawneh HF, Ma L, et al. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy[J]. Retina, 2017, 37(5): 836-843. DOI: 10.1097/IAE.0000000000001269.
10. Corredores Dieb J, Vofo B, Amer R. Long-term experience with anti-tumor necrosis factor-α therapy in the treatment of refractory, non-infectious intermediate, posterior, and panuveitis[J]. Ocul Immunol Inflamm, 2022, 20: 1-8. DOI: 10.1080/09273948.2022.2152983.
11. Al-Janabi A, El Nokrashy A, Sharief L, et al. Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis[J]. Ophthalmology, 2020, 127(3): 410-416. DOI: 10.1016/j.ophtha.2019.08.031.
12. Maalouf G, Andrillon A, Leclercq M, et al. Lower relapses rate with Infliximab versus Adalimumab in sight-threatening uveitis: a multicenter study of 330 patients[J]. Am J Ophthalmol, 2022, 238: 173-180. DOI: 10.1016/j.ajo.2022.02.002.
13. Vallet H, Seve P, Biard L, et al. Infliximab versus Adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network[J]. Arthritis Rheumatol, 2016, 68(6): 1522-1530. DOI: 10.1002/art.39667.
14. Fabiani C, Sota J, Rigante D, et al. Efficacy of Adalimumab and Infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies[J]. Clin Rheumatol, 2018, 37(10): 2805-2809. DOI: 10.1007/s10067-018-4133-z.
15. Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients[J]. Clin Rheumatol, 2019, 38(2): 407-415. DOI: 10.1007/s10067-018-4228-6.
16. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders[J]. Ophthalmology, 2014, 121(3): 785-796. DOI: 10.1016/j.ophtha.2013.09.048.
17. Osswald D, Rameau AC, Terzic J, et al. Risk factors leading to anti-TNF Alpha therapies in pediatric severe uveitis[J/OL]. Front Pediatr, 2022, 10: 802977[2022-03-04]. https://pubmed.ncbi.nlm.nih.gov/35311049/. DOI: 10.3389/fped.2022.802977.
18. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative[J]. Ophthalmology, 2018, 125(5): 757-773. DOI: 10.1016/j.ophtha.2017.11.017.
19. Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490. DOI: 10.1080/14712598.2019.1595578.
20. Zhong Z, Dai L, Wu Q, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease[J/OL]. Nat Commun, 2023, 14(1): 3768[2023-06-24]. https://pubmed.ncbi.nlm.nih.gov/37355662/. DOI: 10.1038/s41467-023-39483-5.
21. Sener H, Evereklioglu C, Horozoglu F, et al. Efficacy and safety of Adalimumab in patients with Behçet uveitis: a systematic review and meta-analysis[J]. Ocul Immunol Inflamm, 2023, 10: 1-9. DOI: 10.1080/09273948.2022.2157288.
22. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations[J]. Rheumatology, 2007, 46(5): 736-741. DOI: 10.1093/rheumatology/kem034.
23. Hu Y, Huang Z, Yang S, et al. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets' disease-associated uveitis: a systematic review and meta-analysis[J/OL]. Front Pharmacol, 2020, 11, 941[2020-06-24]. https://pubmed.ncbi.nlm.nih.gov/32670062/. DOI: 10.3389/fphar.2020.00941.
24. Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behçet's disease following withdrawal of successful anti-tumor necrosis factor treatment[J]. Arthritis Rheumatol, 2017, 69(12): 2380-2385. DOI: 10.1002/art.40235.
25. Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Behçet's disease[J]. Orphanet J Rare Dis, 2021, 16(Suppl 1): S352. DOI: 10.1186/s13023-020-01620-4.
26. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome[J]. Ann Rheum Dis, 2018, 77(6): 808-818. DOI: 10.1136/annrheumdis-2018-213225.
27. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis[J]. N Engl J Med, 2017, 376(17); 1637-1646. DOI: 10.1056/NEJMoa1614160.
28. AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use: US prescribing information[EB/OL]. (2014-09-22)[2023-12-01]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s356lbl.pdf.
29. AbbVie Ltd. HUMIRA [Summary of Product Characteristics][EB/OL]. (2022-10-11) [2023-12-01]. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product- information_en.pdf.
30. Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of Adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003-1011. DOI: 10.1136/annrheumdis-2017-212089.
31. Heiligenhaus A, Klotsche J, Tappeiner C, et al. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis (ICON-JIA) study[J]. Rheumatology, 2019, 58(6): 975-986. DOI: 10.1093/rheumatology/key406.
32. Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis[J/OL]. Acta Ophthalmol, 2022, 100(4): e994-e1001[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34532967/. DOI: 10.1111/aos.15012.
33. Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2007, 66(4): 548-550. DOI: 10.1136/ard.2006.058248.
34. Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab for juvenile idiopathic arthritis-associated uveitis[J]. Clin Exp Ophthalmol, 2005, 33(5): 461-468. DOI: 10.1111/j.1442-9071.2005.01062.x.
35. Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey[J]. J Rheumatol, 2007, 34(5): 1146-1150.
36. Miraldi Utz V, Bulas S, Lopper S, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis[J]. Pediatr Rheumatol Online J, 2019, 17(1): 79. DOI: 10.1186/s12969-019-0383-9.
37. Li Y, Mao X, Tang X, et al. Efficacy and safety of anti-TNFα therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis[J]. Rheumatol Ther, 2021, 8(2): 711-727. DOI: 10.1007/s40744-021-00296-x.
38. Cecchin V, Zannin ME, Ferrari D, et al. Longterm safety and efficacy of Adalimumab and Infliximab for uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2018, 45(8): 1167-1172. DOI: 10.3899/jrheum.171006.
39. Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management[J]. Biomedicines, 2023, 11(2): 629. DOI: 10.3390/biomedicines11020629.
40. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131.
41. Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis[J]. Arthritis Care Res, 2019, 71(4): 482-491. DOI: 10.1002/acr.23610.
42. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis[J]. Arthritis Care Res, 2019, 71(6): 703-716. DOI: 10.1002/acr.23871.
43. Bou R, Adán A, Borrás F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus[J]. Rheumatol Int, 2015, 35(5): 777-785. DOI: 10.1007/s00296-015-3231-3.
44. 中华医学会儿科学分会免疫学组, 中国儿童风湿免疫病联盟, 国家儿童健康与疾病临床研究中心风湿免疫联盟. 幼年特发性关节炎相关葡萄膜炎诊疗中国专家共识(2023)[J]. 协和医学杂志, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.The Subspecialty Group of Immunology, the Society of Pediatrics, Chinese Medical Association, Chinese Alliance of Pediatric Rheumatic and Immunologic Diseases, Alliance of Rheumatic and Immunologic Diseases, National Clinical Research Center for Child Health and Disorders. Chinese Expert Consensus on Juvenile Idiopathic Arthritis-associated Uveitis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 247-256. DOI: 10.12290/xhyxzz.2023-0090.
45. Vitale A, Casa FD, Guerriero S, et al. Efficacy and safety of Adalimumab in pediatric non-infectious non-anterior uveitis: real-life experience from the international AIDA network uveitis registry[J]. Ophthalmol Ther, 2023, 12(4): 1957-1971. DOI: 10.1007/s40123-023-00712-1.
46. Ozer MD, Batur M. Anti-tumor necrosis factor-alpha treatment in pediatric patients with pars planitis: a single-center experience from turkey[J]. Int Ophthalmol, 2023, 43(1): 155-166. DOI: 10.1007/s10792-022-02398-z.
47. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis[J]. Ophthalmology, 2006, 113(5): 860-864. DOI: 10.1016/j.ophtha.2006.01.005.
48. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up[J]. Am J Ophthalmol, 2007, 144(6): 844-849. DOI: 10.1016/j.ajo.2007.08.018.
49. Ucan Gunduz G, Yalcinbayir O, Cekic S, et al. Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: Infliximab versus Adalimumab[J]. J Ocul Pharmacol Ther, 2021, 37(4): 236-240. DOI: 10.1089/jop.2020.0081.
50. Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, et al. Drug monitoring in long-term treatment with Adalimumab for juvenile idiopathic arthritis-associated uveitis[J]. Arch Dis Child, 2019, 104(3): 246-250. DOI: 10.1136/archdischild-2018-315060.
51. Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti-Adalimumab antibodies in juvenile idiopathic arthritis-related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043-1046.
52. Bellur S, McHarg M, Kongwattananon W, et al. Antidrug antibodies to tumor necrosis factor α inhibitors in patients with noninfectious uveitis[J]. JAMA Ophthalmol, 2023, 141(2): 150-156. DOI: 10.1001/jamaophthalmol.2022.5584.
53. Al-Julandani DA, Bagri NK, Tsang N, et al. Outcome of adalimumab monotherapy in paediatric non-infectious uveitis[J]. Pediatr Rheumatol Online J, 2023, 21(1): 21. DOI: 10.1186/s12969-023-00794-y.
54. Bitossi A, Bettiol A, Silvestri E, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study[J/OL]. Mediators Inflamm, 2019, 10: 1623847[2019-02-10]. https://pubmed.ncbi.nlm.nih.gov/30881221/. DOI: 10.1155/2019/1623847.
55. Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study[J]. Br J Ophthalmol, 2018, 102(5): 637-641. DOI: 10.1136/bjophthalmol-2017-310733.
56. Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease[J]. Ocul Immunol Inflamm, 2012, 20(3): 193-197. DOI: 10.3109/09273948.2012.665124.
57. Horiguchi N, Kamoi K, Horie S, et al. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome[J/OL]. Sci Rep, 2020, 10(1): 22227[2020-12-17]. https://pubmed.ncbi.nlm.nih.gov/33335139/. DOI: 10.1038/s41598-020-78718-z.
58. Cordero-Coma M, Calleja-Antolín S, Garzo-García I, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies[J]. Ophthalmology, 2016, 123(12): 2618-2625. DOI: 10.1016/j.ophtha.2016.08.025.
59. Marino A, Real-Fernández F, Rovero P, et al. Anti-Adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations[J]. Clin Rheumatol, 2018, 37(5): 1407-1411. DOI: 10.1007/s10067-018-4057-7.
60. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of Infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study[J]. Rheumatology, 2007, 46(7): 1161-1164. DOI: 10.1093/rheumatology/kem101.
61. Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis[J]. Surv Ophthalmol, 2015, 60(6): 575-589. DOI: 10.1016/j.survophthal.2015.06.004.
62. Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis[J]. Arthritis Care Res, 2023, 75(5): 975-982. DOI: 10.1002/acr.24963.
63. Kalinina Ayuso V, van de Winkel EL, Rothova A, et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis[J]. Am J Ophthalmol, 2011, 151(2): 217-222. DOI: 10.1016/j.ajo.2010.08.021.
64. Adán A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions[J]. Int Ophthalmol, 2010, 30(5): 577-581. DOI: 10.1007/s10792-010-9372-1.
65. Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with Infliximab[J]. Ocul Immunol Inflamm, 2013, 21(6): 468-474. DOI: 10.3109/09273948.2013.779727.
66. Breitbach M, Tappeiner C, Böhm MR, et al. Discontinuation of long-term Adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(1): 171-177. DOI: 10.1007/s00417-016-3497-5.
67. De Simone L, Invernizzi A, Aldigeri R, et al. Effectiveness of Infliximab and interferon alpha-2a for the treatment of Behçet's uveitis: customizing therapy according to the clinical features[J]. Ocul Immunol Inflamm, 2022, 30(2): 506-514. DOI: 10.1080/09273948.2020.1815797.
68. Doycheva D, Zierhut M, Blumenstock G, et al. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results[J]. Br J Ophthalmol, 2014, 98(4): 523-528. DOI: 10.1136/bjophthalmol-2013-303935.
69. Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al. Long-term follow-up of patients with uveitis treated with Adalimumab: response rates and reasons for discontinuation of therapy[J]. Am J Ophthalmol, 2022, 240: 194-204. DOI: 10.1016/j.ajo.2022.03.017.
70. Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of Infliximab[J]. Ocul Immunol Inflamm, 2014, 22(2): 96-101. DOI: 10.3109/09273948.2013.812222.
71. Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy[J]. Jpn J Ophthalmol, 2014, 58(1): 75-80. DOI: 10.1007/s10384-013-0283-3.
72. Köse HC, Yalçındağ N. Clinical follow-up of patients with Behçet uveitis after discontinuation of Infliximab therapy[J]. Ocul Immunol Inflamm, 2022, 30(1): 203-207. DOI: 10.1080/09273948.2020.1774907.
73. Mercier AE, Ribeiro E, Korobelnik JF, et al. Efficacy of anti-TNF-α therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients[J]. Ocul Immunol Inflamm, 2018, 26(3): 477-484. DOI: 10.1080/09273948.2016.1236968.
74. Lerman MA, Lewen MD, Kempen JH, et al. Uveitis reactivation in children treated with tumor necrosis factor Alpha inhibitors[J]. Am J Ophthalmol, 2015, 160(1): 193-200. DOI: 10.1016/j.ajo.2015.04.016.
75. Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of Adalimumab therapy in refractory uveitis due to Behçet's disease[J]. Ophthalmology, 2018, 125(9): 1444-1451. DOI: 10.1016/j.ophtha.2018.02.020.
76. Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term follow-up and optimization of Infliximab in refractory uveitis due to Behçet disease: national study of 103 white patients[J]. J Rheumatol, 2021, 48(5): 741-750. DOI: 10.3899/jrheum.200300.
77. Neves LM, Haefeli LM, Hopker LM, et al. Monitoring and treatment of juvenile idiopathic arthritis-associated uveitis: brazilian evidence-based practice guidelines[J]. Ocul Immunol Inflamm, 2022, 30(6): 1384-1398. DOI: 10.1080/09273948.2021.1876886.
78. Roberts JE, Nigrovic PA, Lo MS, et al. Weekly Adalimumab, an effective alternative for refractory uveitis in children[J/OL]. J Clin Rheumatol, 2022, 28(1): e301-e304[2022-01-01]. https://pubmed.ncbi.nlm.nih.gov/33790207/. DOI: 10.1097/RHU.0000000000001707.
79. Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis[J]. Clin Rheumatol, 2018, 37(2): 549-553. DOI: 10.1007/s10067-017-3890-4.
80. Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study[J]. Ophthalmology, 2014, 121(10): 1877-1884. DOI: 10.1016/j.ophtha.2014.04.042.
81. Tambralli A, Beukelman T, Weiser P, et al. High doses of Infliximab in the management of juvenile idiopathic arthritis[J]. J Rheumatol, 2013, 40(10): 1749-1755. DOI: 10.3899/jrheum.130133.
82. Cunningham ET, Pavesio CE, Goldstein DA, et al. Multiple sclerosis-associated uveitis[J]. Ocul Immunol Inflamm, 2004, 25(3): 299-301.
83. Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers[J]. Curr Neurol Neurosci Rep, 2017, 17(4): 36. DOI: 10.1007/s11910-017-0742-1.
84. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies[J]. Rheumatology, 2010, 49(11): 2217-2219. DOI: 10.1093/rheumatology/keq249a.
85. 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南(2021)[J]. 中华皮肤科杂志, 2021, 54(12): 1033-1047. DOI: 10.35541/cjd.20210643.Chinese Medical Association Dermatology and venereology Branch, Chinese Medical Doctor Association Dermatology Branch, Chinese Association of Integrated Traditional and Western Medicine Dermatology and venereology Professional Committee. Guidelines for the treatment of psoriasis with biologic agents in China (2021)[J]. Chin J Dermat, 2021, 54(12): 1033-1047. DOI: 10.35541/cjd.20210643.
86. Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, et al. The role of TNF-α and anti-TNF-α agents during preconception, pregnancy, and breastfeeding[J/OL]. Int J Mol Sci, 2021, 22(6): 2922[2021-03-13]. https://pubmed.ncbi.nlm.nih.gov/33805757/. DOI: 10.3390/ijms22062922.
87. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases[J]. Arthritis Rheumatol, 2020, 72(4): 529-556. DOI: 10.1002/art.41191.
88. Götestam Skorpen C, Hoeltzenbein M, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016, 75(5): 795-810. DOI: 10.1136/annrheumdis-2015-208840.
89. Tosi GM, Sota J, Vitale A, Rigante D, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis[J]. Clin Exp Rheumatol, 2019, 37(4): 680-683.
90. Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients[J/OL]. RMD Open, 2022, 8(2): e002693[2022-12-01]. https://pubmed.ncbi.nlm.nih.gov/36597972/. DOI: 10.1136/rmdopen-2022-002693.
91. Leal I, Steeples LR, Wong SW, et al. Update on the systemic management of non-infectious uveitis in children and adolescents[J]. Surv Ophthalmol, 2023, 69(1): 103-121. DOI: 10.1016/j.survophthal.2023.01.002.
92. Pocock JM, Vasconcelos JC, Ostör AJ, et al. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?[J]. Rheumatology, 2008, 47(7): 1073-1076. DOI: 10.1093/rheumatology/ken204.
93. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary[J]. Rheumatology, 2019, 58(2): 220-226. DOI: 10.1093/rheumatology/key207.
94. 中国炎症性肠病诊疗质控评估中心, 中华医学会消化病学分会炎症性肠病学组. 生物制剂治疗炎症性肠病专家建议意见[J]. 中华炎性肠病杂志, 2021, 5(3): 193-206. DOI: 10.3760/cma.j.cn101480-20210702-00052.Chinese Inflammatory bowel Disease Diagnosis and Treatment Quality Control Evaluation Center, Chinese Medical Association Gastroenterology Branch Inflammatory Bowel Group. Consensus on biological agents in treating patients with inflammatory bowel disease[J]. Chin J Inflammat Bowel Dis, 2021, 5(3): 193-206. DOI: 10.3760/cma.j.cn101480-20210702-00052.

Previous Article
Research progress on the safety of scleral collagen cross-linking in the prevention and control of pathological myopia

Chinese Journal of Ocular Fundus Diseases

Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content